Cabozantinib S-Malate
The s-malate salt form of cabozantinib, the standard formulation used for treating advanced kidney cancer, liver cancer, and thyroid cancer. By blocking multiple kinase receptors, it disrupts tumor blood supply and cancer cell survival pathways. Salt form selection improves the drug's oral bioavailability.
Masse moléculaire
635,6000 g/mol
TPSA
194,00 Ų
Aires thérapeutiques
Mécanisme d'action
Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.
Structure 2D
Cite this structure
Embed this structure
SMILES
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC.O=C(O)C[C@H](O)C(=O)O
InChI
InChI=1S/C28H24FN3O5.C4H6O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18;5-2(4(8)9)1-3(6)7/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34);2,5H,1H2,(H,6,7)(H,8,9)/t;2-/m.0/s1
Molecular Formula
C32H30FN3O10
HBD / HBA
5 / 12
Liaisons Rotatives
11
Atomes Lourds
46
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
The s-malate salt form of cabozantinib, the standard formulation used for treating advanced kidney cancer, liver cancer, and thyroid cancer. By blocking multiple kinase receptors, it disrupts tumor blood supply and cancer cell survival pathways. Salt form selection improves the drug's oral bioavailability.
Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.
Yes, Cabozantinib S-Malate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2103868. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 25102846. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cabozantinib-s-malate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cabozantinib-s-malate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cabozantinib-s-malate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cabozantinib-s-malate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cabozantinib-s-malate"></drugfyi-drug>